1. Journal of Pain and Symptom Management
Additive Duloxetine for Cancer-Related Neuropathic Pain Nonresponsive or Intolerant to Opioid-Pregabalin Therapy: A Randomized Controlled Trial (JORTC-PAL08) 
Hiromichi Matsuoka, MD, Satoru Iwase, MD, Tempei Miyaji, MSc, Takashi Kawaguchi, PhD, Keisuke Ariyoshi, MSc, Shunsuke Oyamada, MSc, Eriko Satomi, MD, Hiroto Ishiki, MD, Hideaki Hasuo, MD, Hiroko Sakuma, MS, Akihiro Tokoro, MD, Toshiaki Shinomiya, MD, Hiroyuki Otani, MD, Yoichi Ohtake, MD, Hiroaki Tsukuura, MD, Yoshihisa Matsumoto, MD, Yoshikazu Hasegawa, MD, Yuki Kataoka, MD, Masatomo Otsuka, MD, Kiyohiro Sakai, MD, Yoshinobu Matsuda, MD, Tatsuya Morita, MD, Atsuko Koyama, MD, Takuhiro Yamaguchi, PhD 
Journal of Pain and Symptom Management 
DOI: /j.jpainsymman
Copyright © 2019 The Authors Terms and Conditions

2. Fig. 1
Flow chart of study procedures. Participants were randomized (1:1 allocation ratio) into the duloxetine group or the placebo group. Evaluations were made at baseline (at randomization), and on Days 0, 3, and 10. BPI = Brief Pain Inventory.
Journal of Pain and Symptom Management DOI: ( /j.jpainsymman )
Copyright © 2019 The Authors Terms and Conditions

3. Fig. 2
Degree of pain reduction from baseline to Day 10. The plot and the error bar show the proportion and 90% CIs of patients achieving various levels of pain reduction at the completion of the initial treatment period. We analyzed 65 subjects using the BPI-Item 5 over the previous 24 hours. BPI = Brief Pain Inventory.
Journal of Pain and Symptom Management DOI: ( /j.jpainsymman )
Copyright © 2019 The Authors Terms and Conditions